Drug Profile


Alternative Names: LY 293558; NGX 424

Latest Information Update: 14 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly; Johns Hopkins University
  • Developer Raptor Pharmaceutical Corp
  • Class Analgesics; Antimigraines; Isoquinolines; Tetrazoles
  • Mechanism of Action AMPA receptor antagonists; Kainic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Migraine; Thrombosis

Highest Development Phases

  • Discontinued Migraine; Neuromuscular disorders; Thrombosis

Most Recent Events

  • 12 Aug 2014 Discontinued - Phase-I for Neuromuscular disorders in USA (SC)
  • 12 Aug 2014 Discontinued - Phase-I for Thrombosis (In volunteers) in USA (IV)
  • 12 Aug 2014 Discontinued - Phase-II for Migraine in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top